title: Effect of postradiotherapy neck dissection on nonregional disease sites.
abstract: OBJECTIVE
  After chemoradiation for head and neck cancer, more than 90% of patients who achieve a complete clinical response on imaging have their disease regionally controlled without postradiotherapy neck dissections (PRNDs). Because several groups have reported that lymph node involvement also predicts failure at both the primary and distant sites, the extent to which PRND affects nonregional sites of disease remains unclear.
  
  
  OBJECTIVE
  To evaluate how PRND affects local control (LC) and distant control in patients who achieve a complete clinical response.
  
  
  METHODS
  We retrospectively reviewed 287 patients (74 of whom underwent PRND) from the University of Illinois at Chicago Medical Center who were treated for stage III/IV disease with definitive chemoradiation from January 1, 1990, through December 31, 2012.
  
  
  METHODS
  Chemoradiation followed by lymph node dissection or observation.
  
  
  METHODS
  End points evaluated included LC, regional control, freedom from distant metastasis, progression-free survival (PFS), and overall survival using first-failure analysis.
  
  
  RESULTS
  Patients with advanced nodal disease (stage N2b or greater; n = 176) had improved PFS (74.6% vs 39.1%; P < .001), whereas patients with lesser nodal disease had similar PFS. For patients with advanced nodal disease, PRND improved 2-year LC (85.5% vs 53.5%; P < .001), locoregional control with PRND (78.9% vs 45.7%; P < .001), freedom from distant metastasis (79.5% vs 67.5%; P = .03), and overall survival (84.5% vs 61.7%; P = .004) but not regional control (96.9% vs 90.1%; P = .21). The benefit in LC (87.4% vs 66.2%; P = .02) and PFS (80.7% vs 53.4%; P = .01) persisted for those with negative posttreatment imaging results who underwent PRND. On univariate analysis, PRND, alcohol use, nodal stage, and chemoradiation significantly affected 2-year LC and/or PFS. On multivariate analysis, PRND remained strongly prognostic for 2-year LC (hazard ratio, 0.22; 95% CI, 0.07-0.54; P < .001) and PFS (hazard ratio, 0.42; 95% CI, 0.23-0.74; P = .002).
  
  
  CONCLUSIONS
  Postradiotherapy neck dissection improved control of nonregional sites of disease in patients with advanced nodal disease who achieved a complete response after chemoradiation. Thus, PRND may affect the control of nonnodal sites through possible mechanisms, such as clearance of incompetent lymphatics and prevention of reseeding of the primary and distant sites.
authors.affiliation: Department of Radiation and Cellular Oncology, University of Chicago Medical Center, Chicago, Illinois2Department of Radiation Oncology, University of Illinois at Chicago Medical Center, Chicago.
authors.forename: Mark C
authors.initials: MC
authors.lastname: Ranck
authors.affiliation: Department of Radiation Oncology, University of Illinois at Chicago Medical Center, Chicago.
authors.forename: Rainier
authors.initials: R
authors.lastname: Abundo
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, University of Illinois at Chicago Medical Center, Chicago.
authors.forename: Gina
authors.initials: G
authors.lastname: Jefferson
authors.affiliation: Department of Oral and Maxillofacial Surgery, University of Illinois at Chicago Medical Center, Chicago.
authors.forename: Antonia
authors.initials: A
authors.lastname: Kolokythas
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, University of Illinois at Chicago Medical Center, Chicago.
authors.forename: Barry L
authors.initials: BL
authors.lastname: Wenig
authors.affiliation: Department of Radiation and Cellular Oncology, University of Chicago Medical Center, Chicago, Illinois2Department of Radiation Oncology, University of Illinois at Chicago Medical Center, Chicago.
authors.forename: Ralph R
authors.initials: RR
authors.lastname: Weichselbaum
authors.affiliation: Department of Radiation and Cellular Oncology, University of Chicago Medical Center, Chicago, Illinois2Department of Radiation Oncology, University of Illinois at Chicago Medical Center, Chicago.
authors.forename: Michael T
authors.initials: MT
authors.lastname: Spiotto
mesh_terms: D059248:Chemoradiotherapy; D002641:Chicago; D003131:Combined Modality Therapy; D005260:Female; D006258:Head and Neck Neoplasms / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D037981:Neck Dissection; D009367:Neoplasm Staging; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome